Immune checkpoints: cross-disease insights and clinical dilemmas.
9 affiliations
- 1Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
- 2School of Anesthesiology, Naval Medical University, 800 Xiangyin Road, Yangpu District, Shanghai, 200433, China.
- 3Department of Anesthesiology, Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing Medical University, Nanjing, Jiangsu, 210009, China.
- 4Department of Clinical Laboratory, 905th Hospital of PLA, Shanghai, 200052, China. [email protected].
- 5Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. [email protected].
- 6School of Anesthesiology, Naval Medical University, 800 Xiangyin Road, Yangpu District, Shanghai, 200433, China. [email protected].
- 7Department of Anesthesiology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Jiangsu, 210002, Nanjing, China. [email protected].
- 8Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. [email protected].
- 9School of Anesthesiology, Naval Medical University, 800 Xiangyin Road, Yangpu District, Shanghai, 200433, China. [email protected].
Abstract
The immune checkpoints and their inhibitors are revolutionary advances in tumour immunotherapy. Immune checkpoints, however, have a broad spectrum effect. They not only contribute to tumour immune escape, but also are involved in the regulation of the pathopathological processes of numerous inflammatory illnesses, such as sepsis, autoimmune diseases, organ transplant rejection, and viral infections, among others. Today, a considerable gap in knowledge remains regarding immune checkpoints and immune checkpoint inhibitors in non-tumour inflammatory diseases, which remains largely unaddressed. At the same time, the emergence of immune-related adverse events and resistance challenges related to the clinical use of immune checkpoint inhibitors is becoming increasingly prominent, posing a significant obstacle to their application across various diseases. To overcome such issues, this narrative review establishes a systematic framework that links immune checkpoints to various inflammatory diseases and explores the associated therapeutic and clinical challenges. These diseases pose therapeutic and clinical challenges of immune checkpoint inhibitors, which we explore. The paper not only thoroughly describes the clinical picture, pathophysiology, and interventions in immunologic adverse events but also suggests a prospective strategy to confront the existing problems with immune checkpoint inhibitors in 3 dimensions: evaluation, management, and prevention. It will attempt to present a new conceptual framework for a comprehensive understanding of the dual role of immune checkpoints (in maintaining immune homeostasis and facilitating disease progression) and to provide a solid theoretical foundation for the development of safer and more effective cross-disease immunotherapy.
Related
- Retrospective analysis of LAG3, TIGIT, TIM3 and VISTA immune checkpoints expression in hip and knee periprosthetic joint infection
- Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states.
- Decision dilemmas and insights in secondary prevention of ischemic stroke: a case report of an elderly patient with hereditary thrombophilia and high-risk patent foramen ovale
- Anemia in a Cohort of Greek Patients with Sickle Cell Disease: Clinical Insights and Therapeutic Challenges
- Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
BibTeX
@article{shu2026immune,
title = {{Immune checkpoints: cross-disease insights and clinical dilemmas.}},
author = {Yue Shu and Jia-Xin Zhao and Biao-Yu Guo and Yang Liu and Miao Zhou and Ning Ma and Cheng-Long Zhu and Zui Zou},
journal = {Biomarker research},
year = {2026},
month = oct,
doi = {10.1186/s40364-026-01030-x},
url = {https://europepmc.org/article/MED/42958364},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Immune checkpoints: cross-disease insights and clinical dilemmas.
AU - Yue Shu
AU - Jia-Xin Zhao
AU - Biao-Yu Guo
AU - Yang Liu
AU - Miao Zhou
AU - Ning Ma
AU - Cheng-Long Zhu
AU - Zui Zou
PY - 2026
DA - 2026/10/28
JO - Biomarker research
DO - 10.1186/s40364-026-01030-x
UR - https://europepmc.org/article/MED/42958364
AB - The immune checkpoints and their inhibitors are revolutionary advances in tumour immunotherapy. Immune checkpoints, however, have a broad spectrum effect. They not only contribute to tumour immune escape, but also are involved in the regulation of the pathopathological processes of numerous inflammatory illnesses, such as sepsis, autoimmune diseases, organ transplant rejection, and viral infections, among others. Today, a considerable gap in knowledge remains regarding immune checkpoints and immune checkpoint inhibitors in non-tumour inflammatory diseases, which remains largely unaddressed. At the same time, the emergence of immune-related adverse events and resistance challenges related to the clinical use of immune checkpoint inhibitors is becoming increasingly prominent, posing a significant obstacle to their application across various diseases. To overcome such issues, this narrative review establishes a systematic framework that links immune checkpoints to various inflammatory diseases and explores the associated therapeutic and clinical challenges. These diseases pose therapeutic and clinical challenges of immune checkpoint inhibitors, which we explore. The paper not only thoroughly describes the clinical picture, pathophysiology, and interventions in immunologic adverse events but also suggests a prospective strategy to confront the existing problems with immune checkpoint inhibitors in 3 dimensions: evaluation, management, and prevention. It will attempt to present a new conceptual framework for a comprehensive understanding of the dual role of immune checkpoints (in maintaining immune homeostasis and facilitating disease progression) and to provide a solid theoretical foundation for the development of safer and more effective cross-disease immunotherapy.
SN - 2050-7771
ER -